Sangwook Yoon (SangWook Yoon)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Ulcerative Colitis

Top Venues

Clinical drug investigation

This page only lists publications with an associated author ORCID identifier.

Publications

Geert R A M D'Haens, Walter Reinisch, Stefan Schreiber, Fraser Cummings, Peter M Irving, Byong Duk Ye, Dong-Hyeon Kim, Sangwook Yoon, Shomron Ben-Horin
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. Clinical drug investigation (2023)
Rieke Alten, Yoorim An, Dong-Hyeon Kim, Sangwook Yoon, Laurent Peyrin-Biroulet
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. Clinical drug investigation 42 (6) (2022)
Ombretta Viapiana, Soohyun Lee, Sangwook Yoon, Bruno Fautrel
Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17. Clinical drug investigation 42 (2) (2022)
Dasom Choi, Soohyun Lee, Seungmin Kim, Sangwook Yoon
A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10. Clinical drug investigation 42 (4) (2022)
Enrico Fusaro, Patrick Durez, Johannes Wohlrab, Soohyun Lee, Sangwook Yoon, Hubert Marotte
An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar. Immunotherapy (2021)